Novartis (VTX:NOVN) received a CHF 86 target price from stock analysts at Kepler Capital Markets in a research report issued on Tuesday, April 16th, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock.
NOVN has been the subject of a number of other reports. JPMorgan Chase & Co. set a CHF 89 price objective on Novartis and gave the stock a “sell” rating in a report on Wednesday, January 2nd. Deutsche Bank set a CHF 96 price objective on Novartis and gave the company a “neutral” rating in a research note on Friday, January 11th. Barclays set a CHF 75 target price on Novartis and gave the stock a “sell” rating in a research report on Wednesday, January 16th. UBS Group set a CHF 85 target price on Novartis and gave the stock a “neutral” rating in a research report on Friday, January 18th. Finally, Goldman Sachs Group set a CHF 110 target price on Novartis and gave the stock a “buy” rating in a research report on Thursday, January 24th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. Novartis presently has a consensus rating of “Hold” and an average target price of CHF 88.29.
Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.